- Home
- JAZZ vs LLYVA Comparison
JAZZ vs LLYVA Comparison
Compare JAZZ & LLYVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- LLYVA
- Stock Information
- Founded
- JAZZ 2003
- LLYVA 1991
- Country
- JAZZ Ireland
- LLYVA United States
- Employees
- JAZZ N/A
- LLYVA N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- LLYVA Broadcasting
- Sector
- JAZZ Health Care
- LLYVA Industrials
- Exchange
- JAZZ Nasdaq
- LLYVA Nasdaq
- Market Cap
- JAZZ 7.7B
- LLYVA 8.3B
- IPO Year
- JAZZ 2007
- LLYVA N/A
- Fundamental
- Price
- JAZZ $126.54
- LLYVA $96.38
- Analyst Decision
- JAZZ Strong Buy
- LLYVA
- Analyst Count
- JAZZ 14
- LLYVA 0
- Target Price
- JAZZ $178.93
- LLYVA N/A
- AVG Volume (30 Days)
- JAZZ 691.3K
- LLYVA 124.0K
- Earning Date
- JAZZ 11-05-2025
- LLYVA 01-01-0001
- Dividend Yield
- JAZZ N/A
- LLYVA N/A
- EPS Growth
- JAZZ N/A
- LLYVA N/A
- EPS
- JAZZ N/A
- LLYVA N/A
- Revenue
- JAZZ $4,086,695,000.00
- LLYVA N/A
- Revenue This Year
- JAZZ $5.65
- LLYVA N/A
- Revenue Next Year
- JAZZ $5.79
- LLYVA $11.38
- P/E Ratio
- JAZZ N/A
- LLYVA N/A
- Revenue Growth
- JAZZ 4.52
- LLYVA N/A
- 52 Week Low
- JAZZ $95.49
- LLYVA $40.49
- 52 Week High
- JAZZ $148.06
- LLYVA $99.63
- Technical
- Relative Strength Index (RSI)
- JAZZ 56.53
- LLYVA 65.17
- Support Level
- JAZZ $123.88
- LLYVA $91.83
- Resistance Level
- JAZZ $129.50
- LLYVA $99.63
- Average True Range (ATR)
- JAZZ 3.03
- LLYVA 1.94
- MACD
- JAZZ -0.63
- LLYVA -0.21
- Stochastic Oscillator
- JAZZ 29.24
- LLYVA 58.36
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.